Key result
The abstract describes the design and baseline characteristics of the OMEGA-PAD trial evaluating n-3 PUFA supplementation for peripheral artery disease, without reporting efficacy outcomes.
Why the study?
Does high-dose, short-duration dietary oral supplementation of n-3 PUFA improve vascular function and inflammation in patients with established peripheral artery disease?
RCT
Double-blind
Randomized
Does high-dose, short-duration dietary oral supplementation of n-3 PUFA improve vascular function and inflammation in patients with established peripheral artery disease?
The OMEGA-PAD trial is designed to evaluate whether short-term, high-dose n-3 PUFA supplementation improves vascular function and inflammation in patients with peripheral artery disease.
n-3 PUFA supplementation may improve endothelial function in PAD; extends evidence for targeting vascular and inflammatory pathways beyond standard risk factor management.
Despite current consensus guidelines recommending intensive cardiovascular risk factor management for peripheral artery disease (PAD), patients suffering from PAD continue to experience significant morbidity and mortality. This excess morbid burden is at least partially related to impaired vascular function and systemic inflammation. Interventions bridging this gap are critical. Dietary supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA) has been shown to improve endothelial function and reduce inflammation in different cohorts, as well as to decrease cardiovascular events in secondary prevention trials in patients with coronary artery disease. Their effects in the PAD population are, however, less well understood. The OMEGA-PAD trial is a double-blinded, randomized, placebo-controlled trial that examines the impact of a high-dose, short-duration dietary oral supplementation of n-3 PUFA on vascular function and inflammation in patients with established PAD. The purpose of this article is to provide a detailed description of the design and methods of the OMEGA-PAD trial, and a summary of baseline characteristics of the cohort.
No takes yet. Share an insight, caveat, or question.
Grenon et al. (2013) conducted an RCT in Peripheral artery disease. n-3 polyunsaturated fatty acids (n-3 PUFA) vs. Placebo was evaluated on Vascular function and inflammation. The abstract describes the design and baseline characteristics of the OMEGA-PAD trial evaluating n-3 PUFA supplementation for peripheral artery disease, without reporting efficacy outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: